Website
News25/Ratings12
News · 26 weeks35-67%
2025-10-262026-04-19
Mix1790d
- Insider6(35%)
- Other5(29%)
- Earnings3(18%)
- SEC Filings3(18%)
Latest news
25 items- PRCodexis to Report First Quarter 2026 Financial Results on May 7REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-87
- SECSEC Form 8-K filed by Codexis Inc.8-K - CODEXIS, INC. (0001200375) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.SCHEDULE 13G/A - CODEXIS, INC. (0001200375) (Subject)
- SECSEC Form 10-K filed by Codexis Inc.10-K - CODEXIS, INC. (0001200375) (Filer)
- SECCodexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CODEXIS, INC. (0001200375) (Filer)
- PRCodexis Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsQ4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis
- SECSEC Form SCHEDULE 13G filed by Codexis Inc.SCHEDULE 13G - CODEXIS, INC. (0001200375) (Subject)
- PRCodexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing PlatformREDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to deliver meaningfu
- INSIDERChief Scientific Officer Lutz Stefan sold $6,641 worth of shares (5,862 units at $1.13), decreasing direct ownership by 4% to 130,421 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Moore Alison4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERSEC Form 4 filed by Officer Erbez Georgia4 - CODEXIS, INC. (0001200375) (Issuer)
- PRCodexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domest
- PRCodexis to Participate in TD Cowen 46th Annual Health Care ConferenceREDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the TD Cowen 46th Annual Health Care Conference, being held March 2-4, 2026, in Boston, Massachusetts. Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, https://ir.codexis.com. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading provider of enzymatic solutions for efficient
- PRCodexis Achieves ISO 9001:2015 CertificationREDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The official certification reflects Codexis's dedication to delivering manufacturing excellence by applying a high standard of quality assurance throughout all of its processes, including research and development, product manufacturing and testing, delivery, support, and customer service. "Quality assurance is the responsibility of every Codexis employee," said Alison Moore, Codexis's President and Chief Executive Officer. "We are proud to have
- INSIDERChief Scientific Officer Lutz Stefan sold $3,257 worth of shares (2,492 units at $1.31), decreasing direct ownership by 2% to 136,283 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDEROfficer Erbez Georgia sold $5,001 worth of shares (3,826 units at $1.31), decreasing direct ownership by 5% to 66,810 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERPresident and CEO Moore Alison sold $5,001 worth of shares (3,826 units at $1.31), decreasing direct ownership by 2% to 250,506 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERCSO Lutz Stefan sold $7,950 worth of shares (4,685 units at $1.70), decreasing direct ownership by 3% to 138,775 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- PRCodexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide TherapeuticsREDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), today announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform. This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption of the platform. "Part of our mission is to
- INSIDERAmendment: Large owner Opaleye Management Inc. sold $877,846 worth of shares (514,341 units at $1.71) (SEC Form 4)4/A - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERAmendment: Large owner Opaleye Management Inc. sold $1,868,198 worth of shares (1,063,211 units at $1.76) (SEC Form 4)4/A - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. sold $619,580 worth of shares (366,023 units at $1.69) (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERDirector Wolf Dennis P sold $13,988 worth of shares (8,952 units at $1.56), decreasing direct ownership by 6% to 138,951 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERPresident and CEO Moore Alison was granted 85,000 shares, increasing direct ownership by 50% to 254,332 units (SEC Form 4)4 - CODEXIS, INC. (0001200375) (Issuer)
- INSIDERNew insider Lutz Stefan claimed ownership of 143,460 shares (SEC Form 3)3 - CODEXIS, INC. (0001200375) (Issuer)